Literature DB >> 9065538

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease.

D Galasko1, C Clark, L Chang, B Miller, R C Green, R Motter, P Seubert.   

Abstract

CSF levels of tau protein are increased in many patients with Alzheimer's disease (AD). Studies disagree on whether the increase is found in moderate or severe AD to a greater extent than in mild AD, and in two reports there was an inverse correlation between tau levels and cognitive scores. To readdress this question, we measured CSF tau in a group of mildly impaired patients with AD (Mini-Mental State Examination [MMSE] scores > or =20/30) and compared their tau levels with those in age-comparable normal and neurologic controls. We found that the mean level of CSF tau was significantly increased in the AD group compared with the controls, and 29 of 36 patients with AD had levels that exceeded a cutoff determined in a previous study. CSF tau levels did not correlate with MMSE scores. These findings and those of previous studies show that elevated CSF tau levels are found in most patients with AD, occur early in the course of dementia, and may be useful in supporting the diagnosis of AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065538     DOI: 10.1212/wnl.48.3.632

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  Alzheimer's disease and mild cognitive impairment.

Authors:  Brendan J Kelley; Ronald C Petersen
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

2.  Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients.

Authors:  Shuko Takeda; Caitlin Commins; Sarah L DeVos; Chloe K Nobuhara; Susanne Wegmann; Allyson D Roe; Isabel Costantino; Zhanyun Fan; Samantha B Nicholls; Alexis E Sherman; Ana T Trisini Lipsanopoulos; Clemens R Scherzer; George A Carlson; Rose Pitstick; Elaine R Peskind; Murray A Raskind; Ge Li; Thomas J Montine; Matthew P Frosch; Bradley T Hyman
Journal:  Ann Neurol       Date:  2016-08-03       Impact factor: 10.422

Review 3.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

Review 4.  Precision Medicine: Clarity for the Complexity of Dementia.

Authors:  Brenna Cholerton; Eric B Larson; Joseph F Quinn; Cyrus P Zabetian; Ignacio F Mata; C Dirk Keene; Margaret Flanagan; Paul K Crane; Thomas J Grabowski; Kathleen S Montine; Thomas J Montine
Journal:  Am J Pathol       Date:  2015-12-24       Impact factor: 4.307

5.  Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease.

Authors:  A J Green; G Giovannoni; M A Hall-Craggs; E J Thompson; R F Miller
Journal:  Sex Transm Infect       Date:  2000-12       Impact factor: 3.519

Review 6.  Biological markers and the treatment of Alzheimer's disease.

Authors:  D Galasko
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

7.  Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease.

Authors:  A J Green; E J Thompson; G E Stewart; M Zeidler; J M McKenzie; M A MacLeod; J W Ironside; R G Will; R S Knight
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

Review 8.  [Mild cognitive disorder. Questions of definition, diagnosis, prognosis and therapy].

Authors:  A Kurz; J Diehl; M Riemenschneider; R Perneczky; N Lautenschlager
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 9.  Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.

Authors:  Ilan Halperin; Micaela Morelli; Amos D Korczyn; Moussa B H Youdim; Silvia A Mandel
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

10.  The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases.

Authors:  Jan Mares; P Kanovsky; R Herzig; D Stejskal; J Vavrouskova; P Hlustik; H Vranova; S Burval; J Zapletalova; V Pidrman; R Obereigneru; A Suchy; J Vesely; J Podivinsky; K Urbanek
Journal:  Neurol Sci       Date:  2009-01-20       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.